Effects of Testosterone-Lowering Drugs in Patients With Prostate Cancer

Heather S. Jim, PhD
Published: Tuesday, Sep 13, 2016


Heather S. Jim, PhD, associate member in the Health Outcomes and Behavioral Department, Moffitt Cancer Center, discusses the effects of testosterone-lowering drugs used as treatment for patients with prostate cancer.

Androgen-deprivation therapy is associated with several side effects that include depression, cognitive impairment, fatigue, loss of muscle mass, and inflammation, as well as cardiovascular disease and cardiovascular mortality, Jim explains.

Regarding depression, research out of Moffitt Cancer Center suggests that 40% of patients experience clinically significant depressive symptoms after approximately 6 months of ADT. Jim adds that it is important to treat depression not only to help patients feel better, but because depression is associated with increased mortality in patients with prostate cancer.

Heather S. Jim, PhD, associate member in the Health Outcomes and Behavioral Department, Moffitt Cancer Center, discusses the effects of testosterone-lowering drugs used as treatment for patients with prostate cancer.

Androgen-deprivation therapy is associated with several side effects that include depression, cognitive impairment, fatigue, loss of muscle mass, and inflammation, as well as cardiovascular disease and cardiovascular mortality, Jim explains.

Regarding depression, research out of Moffitt Cancer Center suggests that 40% of patients experience clinically significant depressive symptoms after approximately 6 months of ADT. Jim adds that it is important to treat depression not only to help patients feel better, but because depression is associated with increased mortality in patients with prostate cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x